Company Overview - Xencor is a biotechnology company founded on advanced protein engineering technology, recognized for creating antibodies with best-in-class properties [2] - The company has developed multiple marketed products and its technology is widely utilized in the pharmaceutical industry, contributing to a broad pipeline in oncology and autoimmune diseases [2] Pipeline Focus - Xencor is currently concentrating on building its proprietary pipeline of drugs, particularly focusing on solid tumors and T-cell engagers, a rapidly emerging class in cancer treatment [3] - The company aims to define the dosing regimens and efficacy safety profiles for its two lead solid tumor T-cell engager CD3 bispecific antibodies, XmAb819 and XmAb541, with expectations to establish recommended Phase III doses and pivotal plans within the next 12 to 18 months [3]

Summary of Xencor Fireside Chat Company Overview - **Xencor** is a biotechnology company specializing in protein engineering technology, particularly in creating antibodies with best-in-class properties. The company has established a broad pipeline in oncology and autoimmune diseases, focusing on proprietary drug development, especially in solid tumors and T-cell engagers [2][3]. Key Milestones and Focus Areas - Xencor aims to define dosing regimens and efficacy profiles for its lead solid tumor T-cell engagers, **XmAb819** and **XmAb541**, with pivotal trials expected to initiate in 2027 [3][6]. - The company is also focused on developing a **TL1A bispecific** and long-acting monospecific antibody, with key readouts anticipated to enhance value creation in late-phase development [5]. XmAb819 Development Insights - **XmAb819** targets ENPP3-expressing tumor cells while sparing normal tissues, showing a promising 25% response rate in heavily pretreated renal cell carcinoma patients [7][12]. - The design of XmAb819 aims to avoid impacting healthy tissues, with early clinical data indicating excellent tolerability after the initial priming doses [7][11]. - The company is exploring the potential to move XmAb819 into earlier lines of therapy, leveraging its novel mechanism and high ENPP3 expression in clear cell renal cell carcinoma [13][19]. Clinical Development Strategy - Xencor is conducting a sub-study to evaluate XmAb819's monotherapy potential in TKI-naive patients, which could significantly impact the treatment landscape [22]. - The company is also assessing combination therapy opportunities, particularly with PD-1 inhibitors and HIF-2 alpha, to address the unmet needs in renal cell carcinoma [31][32]. XmAb541 and Other Oncology Programs - Initial data from the **XmAb541** program in ovarian and germ cell tumors is being evaluated to determine its potential as a significant opportunity or a niche product [43][51]. - The company is enrolling patients across various tumor types, including papillary renal cell and colorectal cancer, to establish a robust data set for future strategic decisions [57]. Immunology Focus - Xencor's **TL1A** program, particularly **XmAb942**, is designed to have a long half-life and durable suppression of TL1A levels, with a phase 2b global study planned to establish the phase 3 dose [61][62]. - The company aims to position its TL1A program as best-in-class by focusing on efficacy, durability, and dosing convenience, with a target of Q12 week dosing in maintenance [73]. Market Opportunities and Strategic Considerations - Xencor anticipates significant market opportunities in both oncology and immunology, with the potential to capture substantial patient populations [29][82]. - The company is considering partnerships but currently views its assets as capable of being developed independently [60]. Conclusion - Xencor is strategically positioned in the biotechnology sector with a focus on innovative therapies for oncology and immunology. The company is actively advancing its clinical programs and exploring various avenues for maximizing the utility of its drug candidates in the market [1][84].

Summary of Xencor Conference Call Company Overview - **Company**: Xencor (NasdaqGM:XNCR) - **Focus**: Protein and antibody engineering, developing proprietary monoclonal and bispecific antibodies for oncology and autoimmune diseases - **Goal**: To become a fully integrated company by advancing its own programs through clinical trials to market [4][5] Key Priorities - **Clinical Development**: Focus on advancing internal clinical programs, particularly in oncology and autoimmune diseases - **Oncology Programs**: - XmAb819 for renal cell carcinoma - XmAb541 for claudin-6-positive tumors - **Autoimmune Programs**: Launching additional studies, including XmAb412 targeting TL1A and IL-23p19 [6][7] XmAb819 Program Highlights - **Mechanism**: Bispecific antibody targeting ENPP3 and CD3, designed for high engagement and cytotoxicity in tumor cells while minimizing toxicity in normal tissues - **Recent Data**: - 25% objective response rate in heavily pretreated patients with clear cell renal cell carcinoma - Median of 4 prior lines of treatment, with 100% exposure to immune-oncology (IO) and tyrosine kinase inhibitors (TKIs) [11][20] - **Safety Profile**: Dominated by cytokine release syndrome (CRS) and rash, manageable for long-term use [12] - **Future Plans**: - Pivotal trials expected to start in 2027 - Exploring monotherapy potential in earlier treatment lines and other tumor types, including papillary renal cell carcinoma and non-small cell lung cancer [16][18] XmAb541 Program Highlights - **Current Status**: Dose escalation ongoing with a 30% response rate observed in a basket study of germ cell tumors and ovarian cancer - **Future Plans**: Expected to lock down the recommended phase 3 dose later this year [39][40] Competitive Landscape - **XmAb819**: Limited competition in clear cell renal cell carcinoma, with a focus on novel mechanisms and monotherapy activity [31][32] - **XmAb541**: Dense competitive landscape in ovarian cancer, but potential to differentiate as a first-in-class T-cell engager [48] Immunology Programs - **XmAb942 and XmAb412**: Targeting TL1A for autoimmune diseases, with a focus on high potency and long half-life to maximize exposure - **Upcoming Updates**: Full results from phase 1 studies expected at DDW, with a focus on the potential for a long-acting TL1A therapy [49][54] Business Development Strategy - **Focus**: Advancing the pipeline, with potential partnerships to enhance resource capabilities when necessary [58] Market Opportunity - **XmAb819**: Significant market potential in late-line renal cell carcinoma and expansion into other tumor types could double market opportunities [24][26] - **XmAb541**: Addressing high unmet needs in germ cell tumors and ovarian cancer, with a strategic approach to market entry based on clinical data [44] Conclusion - Xencor is positioned to leverage its innovative antibody engineering capabilities to address significant unmet needs in oncology and autoimmune diseases, with promising clinical data supporting its lead programs. The company is focused on advancing its pipeline while exploring strategic partnerships to enhance its development efforts.

Summary of Xencor's Presentation at TD Cowen's 46th Annual Healthcare Conference Company Overview - **Company**: Xencor - **Industry**: Biotechnology - **Focus**: Clinical stage biotech company specializing in protein engineering to develop therapies for oncology and autoimmune diseases [3][4] Core Points and Arguments Clinical Strategy and Pipeline - Xencor is focusing on advancing its clinical strategy starting in 2024, aiming to bring programs into Phase 1 and Phase 2 trials, with a goal of commercializing successful candidates [5] - The company has a strong financial position with over **$600 million** in cash, allowing for flexibility in drug development decisions [6] - Xencor's current clinical portfolio includes two lead oncology programs: **XmAb819** and **XmAb541**, both T-cell engagers targeting specific antigens on tumor cells [7] Oncology Programs - **XmAb819**: - Focused on clear cell renal cell carcinoma, with promising initial data presented at the Triple Oncology Meeting [8] - Plans for pivotal development in **2027** and expansion into additional tumor types [15] - **XmAb541**: - Targeting Claudin-6 in gynecologic tumors, with updates expected later in the year [9][15] Autoimmune Programs - **XmAb942**: - A global Phase IIb study in ulcerative colitis, aiming to provide a best-in-class biologic therapy for patients with high unmet needs [10] - Expected to present final results from a healthy volunteer study at the Digestive Disease Week (DDW) [24] - **XmAb412**: - A bispecific antibody targeting TL1A and IL-23p19, with first-in-human studies starting in the latter half of **2026** [11][12] - **Plamotamab**: - A CD20 T-cell engager in rheumatoid arthritis, with ongoing studies to evaluate its effectiveness compared to traditional monoclonal antibodies [47] - **XmAb657**: - Aiming to mimic CAR T-cell therapy for severe autoimmune diseases, with a focus on delivering durable clinical remission [55] Important Insights - Xencor's protein engineering platform allows for the development of unique therapies that can potentially outperform existing treatments in both oncology and autoimmune diseases [18] - The company emphasizes the importance of understanding the clinical landscape and patient needs to guide its drug development strategy [36] - Xencor's partnerships have provided meaningful royalties and insights that enhance its clinical development capabilities [19] Future Catalysts - Updates on XmAb819 and XmAb541 are expected in the latter half of the year, with pivotal studies planned for **2027** [15][16] - The company is also preparing for the first-in-human study of XmAb412, which is anticipated to provide significant insights into its clinical applicability [27] Conclusion Xencor is positioned to make significant advancements in the biotechnology sector with its innovative drug development strategy, focusing on both oncology and autoimmune diseases. The company is leveraging its strong financial position and unique protein engineering capabilities to address unmet medical needs and drive future growth [20]

Summary of Xencor Conference Call Company Overview - **Company**: Xencor - **Industry**: Biopharmaceuticals, specifically focusing on protein engineering and bispecific antibodies - **Key Executives Present**: Basil Dahiyat (Co-founder, President, CEO), Dane Leone (Executive Vice President, Chief Strategy Officer) [1][2] Core Points and Arguments Expansion into Autoimmune Diseases - Xencor is re-entering the autoimmune disease space with the development of the anti-TL1A antibody, XmAb 942, after previously focusing on oncology [3][4] - The decision to return to autoimmune diseases was driven by the potential for creating differentiated clinical assets [4] - XmAb 942 is designed for high potency and long half-life, targeting TL1A, an inflammatory cytokine linked to inflammatory bowel diseases (IBD) [5][6] Clinical Data and Studies - Phase 1 data for XmAb 942 showed a half-life of over 71 days and sustained suppression of TL1A for over 16 weeks in healthy volunteers [7] - The ongoing Phase 2b study, XENITH-UC, aims to enroll approximately 220 patients to assess clinical remission in ulcerative colitis [11] - The study is designed to facilitate a seamless transition into registration-enabling studies, aiming for a competitive time to market [9] Future Developments - XmAb 412, a bispecific antibody targeting TL1A and IL-23, is expected to enter first-in-human trials in 2026 [10][12] - The combination of TL1A and IL-23 targeting is anticipated to enhance efficacy in IBD treatment [12][13] Other Autoimmune Programs - Xencor is also developing plamotamab, a CD20/CD3 bispecific antibody for rheumatoid arthritis (RA), leveraging their oncology experience to optimize dosing regimens [14][15] - XmAb 657, another bispecific targeting CD19/CD3, is in early development stages for myositis and other indications [16][17] Oncology Developments - XmAb 819, targeting ENPP3 in renal cell carcinoma, has shown a 25% overall response rate in heavily pretreated patients [23][24] - The company plans to expand the use of XmAb 819 into colorectal and lung cancers by 2026 [23][25] - XmAb 541, targeting CLDN6 in gynecologic tumors, is also progressing with early promising data [26][27] Partnerships and Collaborations - Xencor has established partnerships with Amgen and Johnson & Johnson, focusing on bispecific antibodies and other therapeutic areas [30][31] - The partnership with Amgen includes a phase 3 trial for Xaluritamig in metastatic castration-resistant prostate cancer, with potential royalties and milestones for Xencor [30] - Future partnerships are anticipated to enhance Xencor's capabilities and market reach [34][35] Additional Important Information - Xencor aims to be a commercial company, focusing on maximizing stakeholder value through strategic clinical development and potential partnerships [34][36] - The company is well-funded through 2028, allowing for flexibility in decision-making regarding asset management and partnerships [36] This summary encapsulates the key points discussed during the conference call, highlighting Xencor's strategic direction, clinical developments, and partnership strategies in the biopharmaceutical industry.

Core Insights - Xencor is advancing its clinical trial programs with two first-in-class bispecific antibodies, XmAb819 and XmAb541, targeting specific cancer types, showing promising initial results [1][7] - The company reported significant revenue growth in Q2 2025, primarily from milestone payments and royalties, indicating a strong financial position despite not having marketed drugs [2] - Xencor has a diverse pipeline with over a dozen drug candidates at various development stages, showcasing its robust research capabilities [3][4] Group 1: Clinical Development - XmAb819 targets clear cell renal cell carcinoma (ccRCC) and has shown a 25% overall response rate in heavily pretreated patients during Phase 1 trials [1] - XmAb541 is under evaluation for advanced solid tumors expressing CLDN6, with ongoing Phase 1 dose escalation studies [7] - The company plans to recommend a Phase 3 dose for XmAb819 next year and initiate pivotal studies by 2027 [1] Group 2: Financial Performance - Xencor's Q2 2025 revenue reached $43.6 million, an 82% increase compared to Q2 2024, driven by milestone payments and non-cash royalties [2] - The company does not market any approved drugs directly but benefits from royalties on licensed products [2] Group 3: Analyst Sentiment - Despite a 39% decline in stock price year-to-date, analysts like Barclays's Etzer Darout have upgraded Xencor to Overweight, citing positive updates on its pipeline [8][9] - The consensus rating for Xencor stock is Strong Buy, with 12 Buy ratings and a price target suggesting an 85% potential gain over the next 12 months [11]

XmAb819 Clinical Trial - Key Findings - The Phase 1 dose-escalation study of XmAb819 in ccRCC showed a manageable safety profile, with most CRS events being Grade 1/2 and occurring during priming [47, 51, 136] - Correct dose preparation resulted in 4% Grade 3 CRS (2/51), while dose preparation errors led to 28% Grade 3 CRS (5/18) [40, 136] - In the target dose range, correct dose preparation resulted in 6% Grade 3 CRS (1/18), while dose preparation errors led to 50% Grade 3 CRS (3/6) [40, 136] - XmAb819 demonstrated an objective response rate (ORR) of 25% (95% CI: 9-49) and a disease control rate (DCR) of 70% (95% CI: 46-88) in the efficacy-evaluable target dose range (N=20) [55, 89, 125] - The median number of prior regimens for patients in the XmAb819 study was 4 (range: 1-8), with 70% having received ≥3 prior regimens [35, 89, 119] XmAb819 Development & Market Opportunity - Xencor is planning to start a pivotal study of XmAb819 as monotherapy in advanced ccRCC in 2027 [79, 104] - The global RCC market is expected to reach approximately $12 billion by 2030 [80] - In the U S, there are approximately 60,000 new cases of ccRCC per year [84] XmAb541 Early Results - Early data from the Phase 1 dose escalation study of XmAb541 showed promising anti-tumor activity in advanced ovarian cancer, endometrial cancer, and germ cell tumors [4, 93, 97] - The total sales in 1H25 for ovarian cancer drugs were $338 million, and for endometrial cancer drugs were $196 million [100]

Financial Data and Key Metrics Changes - The company is at a clinical inflection point with a focus on oncology and autoimmune disease programs, indicating a strategic reset and a shift towards higher probability success programs [4][5] - The Phase 2b study for the monospecific TL1a program in ulcerative colitis has commenced, with expectations for significant data generation in the coming years [6][7] Business Line Data and Key Metrics Changes - The company has three therapeutic verticals: oncology, autoimmune diseases, and a focus on protein engineering to enhance drug modalities [6][7] - XmAb942, targeting TL1a, has shown a greater than seventy-one day half-life, allowing for a Q12 week dosing schedule, which is a significant improvement over first-generation drugs [12][18] Market Data and Key Metrics Changes - The company is targeting advanced clear cell renal cell carcinoma with XmAb819, which has a high unmet need for innovative treatments [36][40] - The competitive landscape includes other companies developing TL1a and IL-23 inhibitors, with the company aiming to differentiate its products through superior potency and dosing schedules [13][21] Company Strategy and Development Direction - The company aims to leverage its protein engineering platform to create differentiated therapies that maximize patient benefits and advance the standard of care [6][7] - A strategic reset in September 2024 has set the stage for clinical data generation and regulatory approvals, with a focus on bringing the story together for investors [46][47] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the clinical development pipeline and the potential for differentiated clinical profiles that could lead to successful commercialization [19][41] - The company is focused on efficient study designs to expedite the transition to pivotal studies and commercialization [19][33] Other Important Information - The company has initiated multiple clinical studies, including the bispecific TL1A and IL-23 program, with first-in-human studies expected in 2026 [22][24] - The company is also ramping up studies for plamotamab and XmAb657, with regulatory authorizations in progress [26][27] Q&A Session Summary Question: Can you discuss the rationale for targeting ENPP3 in CCRC patients? - The company chose ENPP3 based on internal data and third-party validation, allowing for a faster study design without preselecting patients [36][38] Question: What are the advantages of the bispecific design over combining an anti-TL1A with an IL-23? - The bispecific design allows for a synergistic effect between TL1A and IL-23, potentially leading to better clinical outcomes with a single drug delivery [21][22] Question: What is the expected timeline for initial data readout for plamotamab? - Initial data is expected towards the end of this year or early next year as the study ramps up [33] Question: How does the company plan to differentiate XmAb541 from other therapies? - The company aims to achieve a favorable safety profile and effective dosing regimen to differentiate XmAb541 from existing therapies targeting CLDN6 [44][45]